Haemonetics Corporation HAE recently initiated commercial roll out of its four-channel TEG 6s PlateletMapping ADP & AA assay cartridge globally. Designed to be used with the TEG 6s Hemostasis Analyzer System, the cartridge has already attained the FDA approval in the United States for use in cardiology and cardiovascular surgery. The cartridge has also attained the CE mark and is commercially available in overseas markets with broader indications.
The global commercial availability of the cartridge is expected to bolster Haemonetics’ TEG portfolio.
More About the TEG 6s PlateletMapping Cartridge
The PlateletMapping ADP & AA cartridge is used by clinicians to evaluate a patient’s bleeding and thrombotic risk, which can happen as a consequence of inhibition of platelet function. The assay provides four channels of dried-in-place reagents including HKH (Kaolin with Heparinase), ActF (Activator F), ADP (adenosine-5'-diphosphate) and AA (Arachidonic Acid), enabling clinicians to assess a patient's coagulation ability.
The PlateletMapping ADP & AA cartridge provides clinicians swift and accurate results that are required to study a patient's platelet function. With this information, doctors can easily determine the necessary diagnosis and treatment.
For investors’ notice, the TEG 6s PlateletMapping assay is the only cartridge-based hemostasis analyzer that aids a clinician to study both global hemostasis and platelet function at the site of care.
Per Grand View Research, the global clot management market was worth $1.26 billion in 2015 and is anticipated to reach a value of $1.88 billion by 2024, growing at a CAGR of 4.6%.
In May 2019, Haemonetics attained 510(k) clearance from the FDA to broaden the medical application of its TEG 6s Hemostasis Analyzer System for use in adult trauma settings. This regulatory go-ahead comes on account of the current use for the TEG 6s system in cardiovascular surgery and cardiology procedures, making it the first-ever cartridge-based system available in the United States to study the hemostasis condition in adult trauma patients.
In a year’s time, shares of Haemonetics have gained 17.5% compared with the industry’s 8.2% growth.
Stocks Worth a Look
Haemonetics has a Zacks Rank #2 (Buy).Some other top-ranked stocks from the broader medical space are CONMED CNMD, NuVasive, Inc. NUVA and ResMed RMD, each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CONMED has a projected long-term earnings growth rate of 17%.
NuVasive has an expected long-term earnings growth rate of 10.9%.
ResMed has a long-term earnings growth rate of 12.9%.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
ResMed Inc. (RMD) : Free Stock Analysis Report
NuVasive, Inc. (NUVA) : Free Stock Analysis Report
CONMED Corporation (CNMD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research